Benjamin Ebert: Excited to launch the Center for RAS Therapeutics
Benjamin Ebert, President and CEO of Dana-Farber Cancer Institute, shared a post on LinkedIn by Dana-Farber Cancer Institute adding:
“We are excited to launch the Center for RAS Therapeutics. The first of its kind, this center will pave the way for new treatment options for patients with RAS mutant cancers. I’m incredibly proud of all the research advancements Dana-Farber is making to address the most commonly mutated oncogene across human cancers.
Alice and Andy will do a tremendous job leading the work that the center supports.”
Quoting Dana-Farber Cancer Institute’s post:
“We’re proud to announce the launch of the Center for RAS Therapeutics to target the RAS oncogene in cancer. The first-of-its-kind Center aims to advance new treatment approaches for patients with RAS mutant cancers by bringing Dana-Farber scientists and clinicians together with industry partners and other academic centers to accelerate drug development to improve outcomes for patients.
The Center will be co-directed by Alice Shaw, MD, PhD and Andrew Aguirre, MD, PhD.
RAS is a major driver of some of our most challenging cancers, including lung, pancreatic, colorectal, and endometrial cancers, among others,” said Shaw.
This new Center will enable coordinated efforts among Dana-Farber researchers to advance the most promising new therapies to patients as rapidly as possible.
We will work closely with other academic and industry partners with the goal of improving our understanding of treatment resistance across tumor types, discovering new vulnerabilities in RAS-driven cancers, and conducting the most efficient clinical trials of new therapies, Aguirre added.
The Center’s work will support pre-clinical studies and clinical trials of RAS-directed therapies. A large pipeline of newly developed RAS inhibitors is already in clinical trials or in late preclinical development. Currently, Dana-Farber has many clinical trials open focused on promising new therapies to address RAS-driven cancers.
For more information on the Center, visit www.dana-farber.org.”
Benjamin L. Ebert is the President and CEO of Dana-Farber Cancer Institute. He is also George P. Canellos Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator and an Institute Member of the Broad Institute.
Ebert, a member of the National Academy of Medicine, American Society for Clinical Investigation, and the Association of American Physicians focuses on the molecular basis and treatment of hematologic malignancies, especially myelodysplastic syndromes (MDS).
Also, see OncoDaily’s post on Launching the center for RAS Therapeutics at Dana-Farber Cancer Institute.
More posts featuring Benjamin Eber and Dana-Farber Cancer Institute.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023